Education
About Us
Working with TipRanks
Follow Us
Novonesis (NVZMY)
OTHER OTC:NVZMY
Top Page
Novonesis
(OTC:NVZMY)
Select Model
Select Model
Rating:57Neutral
Price Target:
$58.00
▼(-8.53% Downside)
Action:ReiteratedDate:03/07/26
The score is anchored by mixed financials: strong historical quality but materially weaker and inconsistent recent reported results. Technically, the stock is in a clear downtrend, while valuation is demanding (high P/E) with only modest yield support. Offsetting these risks, the latest earnings call guidance and commentary were notably positive, pointing to continued margin strength and mid-single-digit organic growth despite identified headwinds.
Positive Factors
R&D and Product Pipeline
Large, well-funded R&D program and strong IP protection create a durable product pipeline. High recent launch contribution (25% of sales) and AI-accelerated discovery shorten time-to-market, supporting sustainable organic growth, pricing power and differentiation over the medium term.
High and Expanding Margins
Sustained high gross and EBITDA margins indicate structural cost advantage and pricing power across core businesses. Management guidance keeps margins elevated despite headwinds, implying durable operating leverage that can fund reinvestment, dividends and M&A without eroding profitability.
Strong Balance Sheet and Cash Generation
Very low reported debt and sizable equity cushion, combined with multi-hundred-million euro free cash flow in 2025, provide durable financial flexibility. This supports capex, integration spending, dividends and opportunistic M&A while lowering solvency and refinancing risks over the next several quarters.
Negative Factors
Recent Revenue Decline and Profitability Volatility
Material revenue contraction and inconsistent margins across 2024–2025 reduce visibility into sustainable growth and earnings quality. Such structural variability makes forecasting returns harder, raises the bar for management to demonstrate durable recovery, and increases sensitivity to execution risk.
Higher CapEx and Restructuring Costs
A step-up in capital intensity and restructuring raises medium-term cash needs and can depress free cash flow and ROIC while investments ramp. If new capacity or ERP benefits take longer to realize, elevated capex and integration costs could constrain cash available for dividends or discretionary investments.
Currency Translation and Market Exits
Meaningful FX translation risk and recent country exits (reducing organic growth) create persistent top-line volatility. Translation losses and a smaller addressable footprint can structurally lower reported growth and make operational performance more dependent on favorable currency moves or re-expansion execution.
Novonesis (NVZMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.50B
Dividend Yield1.51%
Average Volume (3M)1.56K
Price to Earnings (P/E)287.4
Beta (1Y)0.24
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees10,582
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.53
Shares Outstanding414,555,050
10 Day Avg. Volume2,114
30 Day Avg. Volume1,559
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)15.45
Price to Sales (P/S)40.34
P/FCF Ratio223.41
Enterprise Value/Market Cap1.74
Enterprise Value/Revenue4.04
Enterprise Value/Gross Profit19.83
Enterprise Value/Ebitda8.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.37
Revenue Forecast (FY)$5.21B
Novonesis Business Overview & Revenue Model
Company DescriptionNovonesis (NVZMY) is a technology-driven company specializing in innovative solutions for the healthcare and life sciences sectors. The company focuses on developing advanced biotechnology products and services aimed at improving patient outcomes and enhancing operational efficiencies within medical institutions. Novonesis is known for its cutting-edge research and development in drug delivery systems, diagnostic tools, and personalized medicine, positioning itself as a leader in the biopharmaceutical landscape.
How the Company Makes MoneyNovonesis generates revenue through multiple streams, primarily by selling its proprietary biotechnology products and services to healthcare providers, research institutions, and pharmaceutical companies. Key revenue streams include direct sales of its advanced drug delivery systems and diagnostic tools, as well as licensing agreements for its patented technologies. Additionally, Novonesis may enter into strategic partnerships with larger pharmaceutical companies for collaborative research and development projects, which can provide significant financial backing and shared revenue opportunities. The company's focus on personalized medicine also opens up avenues for reimbursement from healthcare payers, further enhancing its revenue potential.
Novonesis Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive operational and financial story: solid organic growth (7% FY), strong margins (adjusted EBITDA 37.1%), excellent cash generation and EPS growth, successful M&A integration and a powerful innovation engine with large R&D and IP backing. Balanced against these positives are meaningful but manageable headwinds — chiefly currency impacts, effects from exiting certain countries, one-off integration and restructuring costs, timing variability in Agriculture/Tech, and a temporary step-up in CapEx. Management provided a constructive 2026 outlook (organic growth 5%–7%, EBITDA margin 37%–38%) that already incorporates the noted risks. On balance, highlights materially outweigh the lowlights.Q4-2025 Updates
Positive Updates
Robust Cash Generation and EPS Growth
Operating cash flow of EUR 1.22bn (+EUR 189m YoY). Free cash flow before acquisitions EUR 770m (+15%), equaling 19% of sales. Diluted adjusted EPS EUR 1.49 (+16% YoY); EPS ex-PPA EUR 1.99 (+15%).
Successful Integration and M&A Contribution
Feed Enzyme Alliance acquisition (closed June 2025) contributed ~1% to sales and ~0.25–0.5 ppt to margin as expected; integration progressing and synergies realized ahead of plan (100% run rate of cost synergies a year early).
Innovation and R&D Strength
Launched 33 new biosolutions in 2025 (14 in Q4); ~25% of 2025 sales from products launched in last 5 years. R&D spend >EUR 400m, ~10,000 patents, 85% of 2025 launches IP-protected; AI adoption shortened lead discovery timelines from years to months.
Sustainability and ESG Progress
80% of sales aligned with at least one Sustainable Development Goal; achieved all six 2025 sustainability targets including 100% electricity from renewable sources.
Divisional Outperformance — Human Health & Food & Beverages
Human Health organic sales +10% (FY and Q4) driven by Dietary Supplements and Advanced Health & Nutrition. Food & Beverages organic sales +8% for year and +7% in Q4, driven by dairy, baking, meat and plant-based innovations (e.g., Galaya Smooth, Javora Enhance).
Improved Return Metrics and Capital Allocation
Adjusted return on invested capital (ex-goodwill) 10.1% (+>20% vs prior pro forma). Proposed total dividend payout DKK 6.5 per share (EUR 0.87 total), payout ratio 58.4% (within 40%–60% policy).
Solid Organic Sales Growth
Organic sales grew 7% for FY2025 (4% in Q4) despite exiting certain countries (~1ppt negative for the year). Reported sales grew 5% in EUR for the year.
Strong Profitability and Margin Expansion
Adjusted EBITDA margin of 37.1% for FY2025 (in line with guidance 37%–38%) — +100 bps vs prior year; adjusted gross margin at 59.1% (+240 bps YoY). Q4 adjusted EBITDA margin improved to 36.6% (+40 bps).
Negative Updates
Currency Headwinds
Significant negative FX impact: ~3% headwind to FY sales and ~4% in Q4; currency effects reduced adjusted EBITDA by ~0.5–1.0 ppt and are expected to negatively impact 2026 euro sales by ~2 ppt at current spot rates.
Country Exits Impacting Growth
Exiting certain countries reduced organic sales growth by ~1 ppt for FY2025 (larger divisional impacts: Food & Health ~3 ppt for year, Food & Beverages ~3 ppt for year and ~6 ppt in Q4). Outlook for 2026 includes close to ~1 ppt negative from exits, concentrated in H1.
One-Off Charges and Special Items
Special items of EUR 66m in 2025 (transaction costs, integration and ERP expenses) and guidance of ~EUR 40m special items for 2026 related to integrations and ERP implementation.
Operational Restructuring Costs and Site Closure
Q4 impacted by one-off expenses (~0.5 ppt EBITDA effect) from plant realignment, asset write-down and closure of a smaller site; restructuring aimed at prioritization but caused near-term margin drag.
Mixed Q4 Performance in Planetary Health & Ag/Tech Timing
Planetary Health organic growth slowed to 2% in Q4 and Q4 EBITDA margin fell 90 bps (one-off realignment + currency). Agricultural, Energy & Tech was flat in Q4 due to timing and comparables, with Tech and Agricultural showing lumpy demand.
Q4 Reported Growth Weaker Than Full-Year
Q4 organic sales growth 4% (2% reported in EUR) — softer versus full-year 7% organic — reflecting country exits, currency and timing effects.
Elevated CapEx and Temporary Margin Pressure
CapEx increased to EUR 471m (11.3% of sales, +2 ppt YoY) with guidance of 12%–14% of sales for 2026 to expand production (including dairy culture U.S. project and enzyme capacity in emerging markets). Temporary step-up may pressure free cash flow timing despite strong cash generation.
End-market Uncertainty and Consumer Sentiment Risk
Management flagged potential weaker consumer sentiment (particularly in U.S.) as downside risk for 2026; outlook includes this uncertainty despite a strong start to the year.
Company Guidance
Novonesis guided 2026 for organic sales growth of 5–7% (volume‑driven; includes close to 1 percentage‑point drag from exiting certain countries), with pricing and sales synergies each expected to contribute roughly 1 ppt, around 1 ppt inorganic uplift from the Feed Enzyme Alliance and a ~1 ppt deferred‑revenue boost in Human Health; current FX spot rates imply about a 2 ppt negative translation to euro sales. They expect an adjusted EBITDA margin of 37–38% (continued margin expansion despite ~0.5 ppt currency headwind), ~EUR 40m of special items, net financials of EUR 80–90m, an effective tax rate of 22–23%, CapEx of 12–14% of sales (temporary step‑up to expand capacity and ERP), and year‑end net debt/EBITDA around 1.7 — while noting a good start to the year and a timing‑related inventory uplift in H1 that will be neutral for the full year.Novonesis Financial Statement Overview
Summary
Historically strong profitability and cash generation through 2023, supported by solid equity capitalization and low reported debt in the latest year. However, 2024–2025 results show pronounced revenue decline and inconsistent profitability/cash-flow metrics, reducing confidence in current earnings power and comparability.Income Statement
Profitability has historically been strong (gross margin ~50–58% and net margin ~17–21% in 2020–2023), but the most recent annual periods show a sharp break in trend. Revenue drops materially in 2024 and especially 2025 (large negative growth rates), which makes year-over-year comparability and earnings quality harder to underwrite. Margins shown for 2024–2025 are inconsistent versus prior years and suggest potential one-time effects or reporting/scale changes; net margin is notably lower in 2024 versus the 2020–2023 range, despite 2025 net income appearing unusually high relative to sales.54
Neutral
Balance Sheet
The balance sheet shows solid equity capitalization (equity roughly $10.9–14.0B) and, in the latest year, reported total debt of $0, which implies very low financial leverage currently. However, leverage has been volatile historically (debt-to-equity ranging from ~0.03 to ~0.55 across 2020–2024), indicating the capital structure has shifted meaningfully over time. Return on equity is strong in 2020–2023 (~22–27%), but drops to low levels in 2024 and is shown as 0 in 2025, pointing to weaker recent profitability/measurement inconsistency despite healthy equity.62
Positive
Cash Flow
Cash generation was robust in 2020–2023, with operating cash flow in the ~$4.0–4.4B range and free cash flow improving sharply in 2023. In 2024–2025, operating cash flow and free cash flow fall substantially (to ~$1.0–1.2B operating cash flow and ~$0.66–0.75B free cash flow), and free cash flow growth turns sharply negative in 2025. Cash conversion versus earnings is reasonable in 2020–2024 (free cash flow generally about 28–78% of net income), but 2025 ratios are shown as 0, limiting confidence in current-period cash-to-earnings alignment.58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.16B | 3.83B | 17.90B | 17.55B | 14.95B |
| Gross Profit | 2.24B | 1.81B | 9.72B | 9.58B | 8.62B |
| EBITDA | 1.39B | 8.07B | 5.47B | 6.12B | 5.40B |
| Net Income | 583.60M | 305.80M | 3.02B | 3.68B | 3.15B |
Balance Sheet | |||||
| Total Assets | 16.35B | 15.20B | 28.39B | 27.98B | 24.77B |
| Cash, Cash Equivalents and Short-Term Investments | 295.60M | 284.00M | 1.12B | 1.12B | 1.04B |
| Total Debt | 22.45B | 1.80B | 7.73B | 411.00M | 482.00M |
| Total Liabilities | 5.49B | 4.02B | 14.04B | 13.76B | 12.56B |
| Stockholders Equity | 10.86B | 11.18B | 13.98B | 13.84B | 11.83B |
Cash Flow | |||||
| Free Cash Flow | 750.70M | 660.10M | 2.10B | 1.12B | 2.82B |
| Operating Cash Flow | 1.22B | 1.02B | 4.15B | 4.01B | 4.06B |
| Investing Cash Flow | -1.97B | -199.70M | -2.13B | -2.67B | -2.75B |
| Financing Cash Flow | 753.30M | -703.20M | -1.89B | -1.25B | -1.59B |
Novonesis Technical Analysis
Negative
63.41
Price Trends
61.12
Negative
61.81
Negative
64.25
Negative
Market Momentum
-1.92
Positive
33.05
Neutral
11.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVZMY, the sentiment is Negative. The current price of 63.41 is above the 20-day moving average (MA) of 58.26, above the 50-day MA of 61.12, and below the 200-day MA of 64.25, indicating a bearish trend. The MACD of -1.92 indicates Positive momentum. The RSI at 33.05 is Neutral, neither overbought nor oversold. The STOCH value of 11.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVZMY.
Novonesis Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $22.77B | 14.71 | 33.60% | 2.71% | -12.98% | -11.34% | |
65 Neutral | $18.36B | -21.54 | -3.77% | 1.74% | 2.42% | -196.54% | |
63 Neutral | $12.78B | 21.09 | 22.70% | 1.96% | 3.09% | 12.25% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
59 Neutral | $23.29B | -18.77 | -6.63% | 12.78% | -19.65% | -157.13% | |
57 Neutral | $25.50B | 287.37 | 13.55% | 1.51% | ― | ― | |
57 Neutral | $17.78B | -46.13 | -2.49% | 2.41% | -3.01% | 82.30% |
* Basic Materials Sector Average
NVZMY
Novonesis
54.74
-4.45
-7.52%
IFF
International Flavors & Fragrances
69.61
-10.55
-13.17%
LYB
LyondellBasell
72.30
3.52
5.12%
PPG
PPG Industries
101.89
-9.03
-8.14%
RPM
RPM International
99.76
-14.17
-12.44%
DD
DuPont de Nemours
44.90
13.06
41.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.